ATE448242T1 - Gamma-sekretase-inhibitoren - Google Patents

Gamma-sekretase-inhibitoren

Info

Publication number
ATE448242T1
ATE448242T1 AT03720938T AT03720938T ATE448242T1 AT E448242 T1 ATE448242 T1 AT E448242T1 AT 03720938 T AT03720938 T AT 03720938T AT 03720938 T AT03720938 T AT 03720938T AT E448242 T1 ATE448242 T1 AT E448242T1
Authority
AT
Austria
Prior art keywords
val
group
leu
alkyl
ile
Prior art date
Application number
AT03720938T
Other languages
English (en)
Inventor
Hiroshi Mori
Original Assignee
Hiroshi Mori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshi Mori filed Critical Hiroshi Mori
Application granted granted Critical
Publication of ATE448242T1 publication Critical patent/ATE448242T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
AT03720938T 2002-04-24 2003-04-18 Gamma-sekretase-inhibitoren ATE448242T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002121983 2002-04-24
PCT/JP2003/005017 WO2003091278A1 (fr) 2002-04-24 2003-04-18 Inhibiteurs de gamma secretase

Publications (1)

Publication Number Publication Date
ATE448242T1 true ATE448242T1 (de) 2009-11-15

Family

ID=29267426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720938T ATE448242T1 (de) 2002-04-24 2003-04-18 Gamma-sekretase-inhibitoren

Country Status (11)

Country Link
US (1) US7585938B2 (de)
EP (1) EP1498421B1 (de)
JP (1) JP4404643B2 (de)
KR (1) KR101051249B1 (de)
CN (1) CN1319987C (de)
AT (1) ATE448242T1 (de)
AU (1) AU2003235283A1 (de)
BR (1) BR0304562A (de)
DE (1) DE60329995D1 (de)
NO (1) NO329184B1 (de)
WO (1) WO2003091278A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP2092080A1 (de) * 2006-11-07 2009-08-26 Vib Vzw Diagnose und behandlung akuter t-zellen-lymphoblasten-leukämie
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de) 2006-11-30 2012-04-18 Probiodrug AG Neue inhibitoren von glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2695877A1 (en) 2007-08-09 2009-02-12 Kabushiki Kaisha Yakult Honsha Novel .gamma.-secretase inhibitor
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
US20130195866A1 (en) * 2010-01-19 2013-08-01 Brian J. Bacskai Methods to inhibit neurodegeneration
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
CN102344485A (zh) * 2010-08-05 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 用于治疗阿尔茨海默病的肽类β分泌酶抑制剂及其用途
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI870474A7 (fi) 1986-02-07 1987-08-08 Ciba Geigy Ag Med svavelhaltiga grupper substituerade 5-amino-4-hydroxivalerylderivat.
AU779875B2 (en) 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
US6753410B2 (en) * 2000-03-02 2004-06-22 Merck & Co., Inc. Investigational compounds
WO2001085924A2 (en) * 2000-05-11 2001-11-15 Scios Inc. MODULATION OF η-SECRETASE ACTIVITY
US20030022251A1 (en) * 2001-07-04 2003-01-30 Boehringer Ingelheim Pharma Kg Gamma-secretase in vitro screening assay

Also Published As

Publication number Publication date
WO2003091278A1 (fr) 2003-11-06
BR0304562A (pt) 2004-07-20
CN1656115A (zh) 2005-08-17
US20060205666A1 (en) 2006-09-14
AU2003235283A1 (en) 2003-11-10
KR101051249B1 (ko) 2011-07-21
JPWO2003091278A1 (ja) 2005-09-02
NO329184B1 (no) 2010-09-06
NO20035535L (no) 2004-02-19
EP1498421A1 (de) 2005-01-19
CN1319987C (zh) 2007-06-06
JP4404643B2 (ja) 2010-01-27
EP1498421A4 (de) 2006-05-17
KR20040106370A (ko) 2004-12-17
DE60329995D1 (de) 2009-12-24
US7585938B2 (en) 2009-09-08
EP1498421B1 (de) 2009-11-11
NO20035535D0 (no) 2003-12-11

Similar Documents

Publication Publication Date Title
DE60329995D1 (de) Gamma-sekretase-inhibitoren
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
ATE331708T1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
CO5611113A2 (es) Tripeptidos que poseen un eter de hidroxiprolina de una quinolina sustituida para la inhibicion de ns3 (hepatitis c)
DE69942342D1 (de) Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
SG50602A1 (en) Novel heterocyclic compound
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
MX9707531A (es) Nuevos compuestos heterociclicos.
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
ATE448774T1 (de) Kosmetische zusammensetzung enthaltend ein siegesbeckia extrakt und ein lipopeptid
WO2001072263A3 (de) Verwendung von ectoin oder ectoin-derivaten zum schutz der stressprotein in der haut
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
DK0941975T3 (da) Injiceringscement indeholdende korrosionshæmmere
PT1226160E (pt) Novos peptidos antiarritmicos
DK0624586T3 (da) Substituerede pyrroler
HRP20080330T3 (en) Antitumoral compounds based on kahalalide f
DK0832101T3 (da) Urethan-formidlede, GST-specifikke molekylfrigörelsessystemer
MXPA05013771A (es) Derivados de enalapril-nitroxiderivados y compuestos relacionados como inhibidores de la enzima que convierte la angiotensina para el tratamiento de enfermedades cardiovasculares.
IL153830A0 (en) A PROCESS FOR THE PREPARATION OF alpha' CHLOROKETONES
ID21755A (id) Antijamur azol yang mengandung ester asam amino
PT643061E (pt) Novos antibioticos de cefalosporina e processos para a sua preparacao
AU2003275889A1 (en) Phosphinic acid analogs of glutamate
HRP20050242B1 (en) Synthetic peptides containing unnatural adamantane related amino acids for use as antitumour drugs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties